By
Trending Posts
Can USC’s AI Implant Replace Opioids in Chronic…
USC and UCLA unveil AI-powered, wireless spinal implant that delivers real-time, adaptive pain relief without drugs, batteries, or…
Can Tampa General’s New AI Ambient Tech Redefine…
AI-powered voice technology by Microsoft brings ambient documentation to frontline nurses, boosting care quality and clinical efficiency Key…
Can Ottai’s New AI Biosensor Reshape Chronic Disease…
AI-powered wearable from Oxford-founded Ottai offers real-time insights, personalized support, and voice-driven healthcare experience Key Takeaways AI-Driven Transformation…
Accelerating Drug Discovery with Artificial Intelligence: Strategic Insights…
Executive SummaryThe convergence of artificial intelligence (AI) and drug discovery is a strategic imperative. Pharmaceutical giants including Sanofi,…
Is Merck’s WINREVAIR Set to Redefine First-Year PAH…
Key Takeaways:• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in…
Can Sanofi’s Sarclisa-VRd Regimen, Backed by EMA’s CHMP,…
Key Highlights EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible AdultsOn June 23, 2025, Sanofi announced…
Could Lilly’s Oral GLP-1 Orforglipron Revolutionize Type 2…
Key Highlights Orforglipron Delivers Clinically Meaningful Glycemic and Weight ImprovementsThe ACHIEVE-1 Phase 3 trial established orforglipron’s efficacy, showing…
How Caris Life Sciences’ $7.6B IPO the Breakout…
Key Highlights AI Meets Molecular Medicine: A New TechBio Contender EmergesCaris Life Sciences’ successful IPO positions it as…
Is Eli Lilly’s $1.3B Acquisition of Verve the…
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…
Trending Posts
Latest Stories
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind,…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40 Years of Limited Progress?
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC Treatment?
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive…
Gallery
